-
If you purchased shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO), you have certain options and you should contact the Shareholders Foundation, Inc.
-
To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Investigation Overview
August 2, 2012 (Update) -- On August 1, 2012, after the market closed, Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that the Center for Biologics Evaluation and Research (CBER) of the FDA has issued a complete response letter for Baxter's HyQ Biologics License Application. Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) dropped from $$8.61 per share on August 1, 2012, to ...
You must register (for free) or login to view the entire investigation.
